Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

This study has been completed.
Atlantic Research Group
Information provided by (Responsible Party):
Green Cross Corporation Identifier:
First received: July 26, 2011
Last updated: January 9, 2014
Last verified: January 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)